BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst to Report First Quarter 2024 Financial Results on May 6

22 4月 2024 07:00:50 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

19 4月 2024 11:04:56 条件 NetDania Notify

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

17 4月 2024 04:30:39 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

05 4月 2024 09:45:07 条件 NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

04 4月 2024 15:51:53 条件 NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 4月 2024 09:45:12 条件 NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 4月 2024 07:00:23 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

02 4月 2024 12:00:22 条件 NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

25 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

14 3月 2024 13:48:51 条件 NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 3月 2024 07:01:47 条件 Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

26 2月 2024 07:00:05 条件 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

23 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

21 2月 2024 16:01:58 条件 Nasdaq GlobeNewswire

BioCryst Launches ORLADEYO® (berotralstat) in Italy

19 2月 2024 07:54:52 条件 Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

12 2月 2024 07:00:53 条件 Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

05 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 2月 2024 07:00:48 条件 Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

05 1月 2024 16:01:00 条件 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 1月 2024 16:01:59 条件 Nasdaq GlobeNewswire